Strategic Transition to QMSR: Navigating the FDA’s Global Alignment and the New Compliance Landscape
[中譯] 邁向 QMSR 的策略轉型：掌握 FDA 的全球接軌與全新合規局勢

1. Executive Summary: The 2026 Tectonic Shift
[中譯] 1. 管理摘要：2026 年的結構性劇變

The medical device regulatory environment is currently undergoing its most significant transformation in nearly three decades. On February 2, 2026, the industry will officially exit the era of the 21 CFR Part 820 "Quality System (QS) Regulation" and enter the "Quality Management System Regulation" (QMSR) era. This transition represents a deliberate move by the FDA to harmonize domestic requirements with international standards, fundamentally altering how quality systems are designed, documented, and inspected. For C-suite executives and QA/RA directors, this date is a mandatory pivot point for global market access and legal compliance. Based on the FDA’s final mandates, several core insights define this transition:
[中譯] 醫療器材法規環境正經歷近三十年來最顯著的變革。自 2026 年 2 月 2 日起，產業將正式告別 21 CFR Part 820「品質系統（QS）法規」時代，全面步入「品質管理系統法規」（QMSR）新紀元。此轉型象徵 FDA 刻意將其國內要求與國際標準調和，徹底改變了品質系統的設計、文件化與稽查模式。對於高層管理者與品質保證/法規事務主管而言，此日期是維繫全球市場准入與法律合規的強制性轉折點。依據 FDA 的最終指令，本次轉型核心洞察如下：

• Total Integration of ISO 13485:2016: The FDA is incorporating this international consensus standard by reference, replacing the legacy QS regulation with a global quality language.
  [中譯] 全面整合 ISO 13485:2016： FDA 透過直接參照引用此國際共識標準，以全球通用的品質語言取代傳統品質系統法規。
• Substantial Economic Impact: The convergence is projected to result in an annualized net cost savings of approximately $532 million for the industry, primarily through the reduction of redundant documentation.
  [中譯] 顯著的經濟效益： 此法規調和預計每年可為產業節省約 5.32 億美元的淨成本，這主要歸功於冗餘文件的減省。
• Operational Threats and Inspectional Shocks: Compliance verification is shifting to Compliance Program (CP) 7382.850. Crucially, the long-standing "shield" that protected internal audit and management review reports from FDA discovery is being revoked. This shift is driven by a clear economic and regulatory logic: by removing unnecessary duplicative requirements, the FDA aims to provide patients with more efficient access to safe and effective medical devices while allowing manufacturers to maintain a single, streamlined quality management system (QMS) for multiple jurisdictions.
  [中譯] 營運威脅與稽查衝擊： 合規驗證全面轉移至 Compliance Program (CP) 7382.850 方案。最關鍵的是，長期保護內部稽核報告與管理審查會議紀錄免受 FDA 調閱的「保護傘」已被廢除。此轉變背後有著清晰的經濟與法規邏輯：透過免除不必要的重複要求，FDA 旨在讓患者能更有效率地取得安全且有效的醫療器材，同時使藥廠得以在多個管轄區域維持單一且精簡的品質管理系統（QMS）。

2. The Logic of Convergence: Economic Gains vs. SME Vulnerabilities
[中譯] 2. 趨同的邏輯：經濟收益 vs. 中小企業的脆弱性

The transition from "Local Dialects" (FDA-specific QS) to a "Global Language" (ISO 13485) is a strategic necessity in a multinational marketplace. Historically, firms were forced to maintain dual-track systems to satisfy both US and international regulators—an inefficiency that delayed market entry and inflated overhead. However, the impact of this convergence is not uniform. While global leaders gain efficiency, Small and Medium Enterprises (SMEs) face significant upfront burdens.
[中譯] 在多國市場中，從「地方方言」（FDA 特定的品質系統）過渡到「全球通用語言」（ISO 13485）是一項戰略必然。在過去，企業被迫維持雙軌並行的系統以同時滿足美國與國際監管機構，這種低效率延誤了市場進入並拉高了管理成本。然而，這項趨同所帶來的衝擊因企業規模而異。當全球龍頭企業獲得效率提升時，中小企業（SMEs）與僅經營國內市場的藥廠卻面臨巨大的前期負擔。

The Dual Impact of Regulatory Convergence
[中譯] 法規趨同的雙重影響對照表

Global Leaders (Opportunities) [中譯] 全球領先企業（機會）	SMEs & Domestic-Only Firms (Threats) [中譯] 中小企業與僅限國內市場之藥廠（威脅）
Streamlined Compliance: Elimination of redundant effort for firms already compliant with ISO 13485. [中譯] 精簡合規： 對於已符合 ISO 13485 的企業，可完全免除重複的資源耗費。	High Initial Capital Outlay: Firms not currently in compliance face an estimated $49.8 million in costs for updating IT systems, training, and document policy. [中譯] 高昂的前期資本投入： 目前尚未合規的藥廠面臨全球總計估算約 4,980 萬美元的升級成本，用於翻新資訊系統、教育訓練與文件政策。
Operational Efficiency: Reduction in overhead via Unified Training Programs and harmonized document maintenance. [中譯] 營運效率增長： 透過統一的訓練計畫與整合型文件維護，降低組織間接管理成本。	Learning Curve Risk: Personnel at smaller firms must rapidly master a more explicit, documented risk-based framework. [中譯] 學習曲線風險： 小型企業的人員必須在極短時間內，迅速熟練一套更為明確且注重書面記錄的風險管理架構。
Market Agility: Faster introduction of devices into multiple regions through aligned regulatory expectations. [中譯] 市場敏捷度： 受惠於監管期待趨於一致，能將醫療器材更快速地推向多個目標市場。	Audit Vulnerability: Lack of legacy ISO experience may lead to increased 483 observations during the 2026 transition. [中譯] 稽查脆弱性： 由於缺乏過往的 ISO 實務經驗，在 2026 年過渡期間可能導致 FDA 483 觀察報告的缺失數量顯著增加。

The "So What?" layer for leadership is clear: this is a move from "compliance by checking boxes" to "compliance by risk-based culture." The QMSR forces firms to integrate risk management into every facet of the QMS. Compliance will no longer be verified by simply proving a procedure exists; it will be verified by demonstrating how the system identifies and mitigates risk throughout the product life cycle.
[中譯] 對於高層管理者的「核心本質」非常明確：這是一場從「流於形式的勾選合規」到「深植組織的品質風險管理文化」之全面轉移。QMSR 強制企業將品質風險管理整合至品質管理系統的每一個層面。未來合規的判定不再僅僅是證明特定程序書存在，而是必須實際展示該系統如何在產品整個生命周期中，有效確認並減低危害。

3. The New Inspection Paradigm: Deconstructing CP 7382.850
[中譯] 3. 全新稽查範式：深度剖析 CP 7382.850

Verification of compliance is shifting from the well-known Quality System Inspection Technique (QSIT) "four subsystems" model to a new framework. As of February 2, 2026, FDA investigators will utilize Compliance Program (CP) 7382.850, a script specifically designed to audit against the QMSR.
[中譯] 合規驗證模式正從眾所皆知的 QSIT「四大子系統」模式移轉至全新架構。自 2026 年 2 月 2 日起，FDA 稽查員將全面啟用 Compliance Program (CP) 7382.850 指引，這是一套專門為了針對 QMSR 執行法規稽核所設計的全新劇本。

3.1. The Death of QSIT
[中譯] 3.1. QSIT 的終結

The QSIT model is retired. In its place is a more holistic, risk-based approach where investigators follow the QMSR framework. They will no longer look at subsystems in isolation but will instead seek the "connective tissue" between risk management, product realization, and improvement clauses.
[中譯] 傳統 QSIT 檢查模式已正式宣告除役。取而代之的是一套更為全面且以風險為導向的方法，稽查員將依循 QMSR 架構開展評估。他們不會再孤立地審查各個子系統，而是會全面尋找風險評價、產品實現與持續改進條款之間的「結締組織」。

3.2. Loss of the "Internal Audit Shield"
[中譯] 3.2. 內部稽核「保護傘」的失效

The most significant strategic shock is the revocation of § 820.180(c). Under the legacy regulation, the FDA generally refrained from reviewing internal audit reports and management review minutes. Under QMSR, this "shield" is gone; these documents are now fully discoverable. Management must understand the "Immunity Analogy": The FDA does not care if your organization is "sick" (identifies an error); they care if you lack the "immunity" (a robust CAPA system) to heal yourself. Attempting to purge or "sanitize" internal audit findings is a fatal trap. Incomplete or "perfect" audit records over multiple years will be viewed as a "Red Flag," indicating the QMS has lost its ability to self-heal. Furthermore, regardless of ISO nomenclature, the FDA’s legal authority to inspect these records remains absolute under Section 704 of the FD&C Act.
[中譯] 本次變革在策略上帶來的最大衝擊，莫過於聯邦法典第 820.180(c) 條文的廢除。在舊制法規下，FDA 通常會主動避開審閱企業的內部稽核報告與管理審查會議紀錄。但在 QMSR 架構下，這道「保護傘」已不復存在，此類文件現已完全屬於可調閱範圍。管理階層必須理解「免疫力比喻」：FDA 並不在意你的組織是否「生病」（發現錯誤），他們真正在乎的是你是否缺乏「免疫力」（一套健全的矯正預防措施 CAPA 系統）來進行自我修復。企圖刪減或「美化」內部稽核發現是一場致命陷阱。連續多年不完整或過於「完美無瑕」的稽核紀錄將被視為「重大警訊（Red Flag）」，意味著該 QMS 已喪失其自我修復能力。此外，不論 ISO 的名詞如何變更，依據 FD&C 法案第 704 條，FDA 審查這些紀錄的法定權限仍是絕對且不可動搖的。

3.3. The ISO Certificate Fallacy
[中譯] 3.3. ISO 證書的迷思與誤區

A common C-suite misconception is that an ISO 13485 certificate serves as a "Get Out of Jail Free" card. It does not. The FDA refuses to issue ISO 13485 certificates and will not rely on them for regulatory oversight. Crucially, ISO audits are calendar-triggered, whereas FDA inspections remain risk-triggered, often launched by post-market data such as Medical Device Reports (MDRs) and Recalls.
[中譯] 高層管理者常存有一個誤解，認為持有 ISO 13485 證書就等同於獲得免死金牌。事實並非如此。FDA 拒絕核發任何 ISO 13485 證書，且絕不會依賴該證書來替代其官方的法規監督職責。至關重要的一點是，ISO 驗證稽核是採取固定的「行事曆週期觸發」，而 FDA 的實地稽查則是「品質風險觸發」，通常是由上市後數據（如醫療器材不良事件報告 MDR 或產品召回事件）直接發動。

4. The Friction Points: "Other Applicable FDA Requirements" (OAFRs)
[中譯] 4. 法規衝突點：美國市場特定要求（OAFRs）

While the QMSR adopts ISO 13485, it maintains several "American-specific" mandates to satisfy the FD&C Act. Organizations must explicitly link ISO clauses to these OAFRs:
[中譯] 儘管 QMSR 採納了 ISO 13485 標準，但為了符合美國 FD&C 法案，它仍保留了數項「美國市場特有」的法定強制義務。企業必須將國際標準條款明確連結至這些法規特定要求：

• Device Identification: Clause 7.5.8 must link to 21 CFR Part 830 (UDI).
  [中譯] 器材識別： 國際標準 Clause 7.5.8 必須串聯至 21 CFR Part 830 (醫療器材單一識別碼 UDI)。
• Traceability: Clause 7.5.9.1 must link to 21 CFR Part 821 (Tracking) for life-sustaining devices.
  [中譯] 追溯性： 國際標準 Clause 7.5.9.1 針對生命維持器材，必須串聯至 21 CFR Part 821 (器材追蹤要求)。
• Reporting: Clause 8.2.3 must link to 21 CFR Part 803 (MDR).
  [中譯] 報告通報： 國際標準 Clause 8.2.3 必須串聯至 21 CFR Part 803 (醫療器材不良事件報告 MDR)。
• Corrections and Removals: Clauses 7.2.3 and 8.3.3 must link to 21 CFR Part 806.
  [中譯] 矯正與移除回收： 國際標準 Clause 7.2.3 與 8.3.3 必須串聯至 21 CFR Part 806 法規。

ISO 13485 is relatively general regarding labeling. However, the FDA has retained strict requirements under § 820.45. Unlike the broader ISO standard, the FDA mandates human-verified inspection of labeling for accuracy (UDI, expiration dates, etc.) before release. Automated readers are permitted but must be supported by designated human oversight to prevent the labeling errors that remain a primary cause of recalls.
[中譯] ISO 13485 在標籤標示方面的規定相對籠統。然而，FDA 堅持保留了聯邦法典第 820.45 條的嚴格限制。不同於標準國際條文，FDA 強制要求在放行出廠前，必須由專人進行包裝標籤準確性（包括 UDI、末效日期等）的人工核對稽核。雖然允許引入自動化條碼掃描讀取設備，但後端仍必須配置指定的人員覆核把關，以徹底杜絕至今仍高居器材召回主因的標籤錯誤。

5. Defensive Strategy: Preparing for 2026 Implementation
[中譯] 5. 防禦性合規策略：為 2026 年實施做好準備

The implementation window is a period of high-risk transition. Our defensive strategy must prioritize continuity over massive revision.
[中譯] 轉型導入期屬於高風險的過渡階段。我們的防禦性策略核心必須將品質系統的連續性置於首位，而非展開破壞性的盲目大改。

The Mapping Document Strategy
[中譯] 編制差異分析對照表的防禦策略

For legacy records—specifically CAPAs and Design History Files (DHF) from 2024–2025—management must forbid the retroactive rewriting of records. Rewriting history to match new ISO templates creates a significant "red flag" for investigators. Instead, firms must utilize a Mapping Document (Difference Analysis). This "bridge" document links legacy records to QMSR/ISO clauses, demonstrating the transition logic to an inspector without compromising the integrity of the original data. This is a defensive necessity to prevent 483 observations during the first post-2026 audit.
[中譯] 面對既有品質歷史檔案（特別是 2024 至 2025 年間建立的 CAPA 與設計歷程檔案 DHF），管理階層必須嚴格禁止任何事後回溯改寫的行為。為了迎合全新 ISO 範本而重新篡改歷史紀錄，在稽查員眼中無疑是嚴重的誠信瑕疵。相對地，藥廠應建立一套品質系統「差異分析對照表（Mapping Document）」。這份關鍵的橋接文件能清晰勾勒出歷史紀錄與全新 QMSR/ISO 條款之間的對應關係，在不破壞原始數據完整性的前提下，向官方稽查官展現品質系統過渡的邏輯鏈結。這是在 2026 年後初次迎來實地查核時，阻絕 FDA 483 觀察報告缺失的防禦性防線。

Expansion of Risk Management
[中譯] 品質風險管理範疇的向外擴張

Under QMSR, risk management must extend to the entire QMS. Specifically, Clause 7.4 (Purchasing) now requires risk-based control of all suppliers. C-suite leaders must recognize that consultants providing regulatory or technical advice are technically "suppliers" and must be subject to risk-based evaluation and monitoring commensurate with the risk of the device.
[中譯] 在 QMSR 的規範要求下，品質風險管理必須全面覆蓋至整套品質管理系統。特別是國際標準 Clause 7.4（採購管制），現明確要求針對所有供應商實施風險導向的管制策略。決策高層必須深刻意識到，提供法規遵循或技術諮詢的外部顧問公司在定義上皆屬於「供應商」，必須根據器材本身的風險度量嚴重度，對其納入品質風險評估與後續評估的常規監控中。

6. Macro Insights: The Structural Risks of FDA "Following" ISO
[中譯] 6. 總體宏觀洞察：FDA 亦步亦趨跟隨 ISO 的結構性風險

This transition introduces a subtle but profound philosophical tension: the FDA is relinquishing its role as the absolute, independent standard-setter by "anchoring" its federal regulation to an external body.
[中譯] 此法規轉型帶來了微妙卻深遠的法理哲學衝突：當 FDA 選擇將其聯邦法規「錨定」於外部國際組織時，某種程度上等同於部分讓渡了其作為絕對、獨立標準制定者的傳統角色。

The Honeymoon Period and Future Divergence
[中譯] 蜜月期與未來的法規分歧危機

We are currently in a "Honeymoon Period" of global harmony. However, a potential "Time Bomb" exists regarding future divergence. ISO standards are updated by international committees where the FDA is only one of many voices. If a future version of ISO 13485 becomes more lenient, the FDA may be forced to issue a wave of new "supplementary requirements," effectively ending the era of simplicity.
[中譯] 我們目前正處於全球法規和諧的「蜜月期」。然而，隱藏其中的「定時炸彈」則是未來標準一旦分歧時的應對難題。ISO 國際標準是由國際委員會共同編修，FDA 在該體系中僅是眾多話語權的其中一員。倘若未來版本的 ISO 13485 朝向寬鬆修正，FDA 勢必得被迫密集發布新一輪的「附加補充要求」，這將使得好不容易實現的單一簡化時代戛然而止。

"Safety and Performance" vs. "Safety and Effectiveness"
[中譯] 「安全與功能表現」對比「安全與有效性」的法律底線

A critical legal distinction persists. ISO 13485 uses the term "Safety and Performance," whereas the FD&C Act mandates "Safety and Effectiveness." The FDA has clarified that within Clause 0.1 of ISO 13485, "Safety and Performance" will be construed as "Safety and Effectiveness." This is a non-negotiable legal baseline; manufacturers cannot argue that a device’s "performance" justifies a lack of "effectiveness" as defined by US law.
[中譯] 兩者間存在著不容忽視的法律邊界區隔。ISO 13485 所慣用的核心術語為「安全與功能表現（Safety and Performance）」，但美國 FD&C 法案在法定底線上強制要求的則是「安全與有效性（Safety and Effectiveness）」。FDA 對此已明確發出官方聲明：在 ISO 13485 的 Clause 0.1 架構下，「安全與功能表現」將被嚴格等同詮釋為「安全與有效性」。這是不可談判的法定底線；製造藥廠絕不能在法庭或稽查中宣稱器材的某種「功能表現」，足以開脫或證成其缺乏美國法律所定義的實質「有效性」。

Final Conclusion for Management
[中譯] 管理階層最終結論

The 2026 shift is a transition of terms, but the core pillars of a quality culture remain: Risk Management and Self-Healing Systems (CAPA). Organizations that embrace the transparency required by the loss of audit shields and utilize the next two years to map legacy systems to the new global language will not only survive the transition but will thrive in the harmonized global market.
[中譯] 2026 年品質管理系統的法規更迭表面上是名詞條文的重組，然而維持品質文化的兩大核心支柱始終不變：那便是全面性的品質風險管理，以及具備卓越自我修復能力的補救修復（CAPA）系統。唯有正面擁抱內部稽核保護傘失效後所帶來的資訊透明化，並善用過渡期確實建立新舊架構對照鏈結的藥廠，方能在此波全球法規調和的浪潮中化被動為優勢，順利搶占多國市場的法規放行先機。